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Abstract
Background: Bone metastasis due to gastric cancer is rare, and the clinical features have not been fully evaluated.
We investigated the clinical features, treatment outcomes, and prognostic factors in gastric cancer patients with
bone metastasis.
Methods: We retrospectively collected data on 34 consecutive patients who were diagnosed radiologically with
bone metastasis due to gastric cancer. We estimated the overall survival after the diagnosis of bone metastasis
using the Kaplan-Meier product-limit method and evaluated which clinicopathological factors were associated with
prognostic factors for survival using univariate and multivariate Cox proportional hazards regression models.
Results: The treatment for the primary tumor was surgery in 16 patients (47.1%) and chemotherapy in 18 patients
(52.9%). The median serum alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels at the time of bone
metastasis were 375.5 and 249 IU/L, respectively. Ten patients (29.4%) were diagnosed with bone metastasis and
gastric cancer at the same time. The 6-month survival rate after the diagnosis of bone metastasis was 63.8%, and
the median survival time was 227.5 days. Multivariate analysis revealed that metachronous metastasis (p = 0.035)
and extraosseous metastasis (p = 0.028) were significant risk factors for poor survival.
Conclusions: The prognosis of gastric cancer with bone metastasis was poor, and metachronous metastasis and
extraosseous metastasis were shown to be poor prognostic factors. Serum ALP, LDH, and tumor markers are not
always high, so aggressive diagnosis using appropriate modalities such as bone scan, MRI, or PET-CT may be
necessary in routine practice even in asymptomatic patients.
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Background
Although the incidence of gastric cancer has decreased
in developed countries, it is the second most common
cancer worldwide and two thirds of cases are found in
developing countries [1]. The main sites of metastasis of
gastric cancer are the liver and lungs, and the incidence
of bone metastasis due to gastric cancer is only 0.9–2.1%
[2], although there may be many gastric cancer patients
who have not been diagnosed with metastasis clinically
since the reported frequency of bone metastasis in gas-
tric cancer was 13.4–15.9% in an autopsy series [3].
The median survival times of gastric cancer patients
with bone metastasis are 3–4 months after the detection
of bone metastasis [4, 5]. Since bone metastasis can
cause intractable pain leading to poor quality of life, ap-
propriate treatment strategies are essential for the af-
fected patients [2]. Although the clinical characteristics
and poor prognostic factors have been reported, they are
not well-defined [4–7]. In this study, we retrospectively
examined the clinicopathological features, treatment
outcomes, and prognostic factors for survival in gastric
cancer patients with bone metastasis.
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Methods
This study was approved by the institutional review board
at Sakai City Medical Center. We retrospectively collected
data on 34 consecutive patients who were radiologically
diagnosed with bone metastasis due to gastric cancer be-
tween January 2010 and December 2015. All tumors were
histologically diagnosed as adenocarcinoma with the
stomach, which was recognized as primary tumor. Bone
metastases have been treated after the clinical diagnosis
by CT, PET-CT, bone scintigraphy, or MRI and after con-
firming that there were no other suspicious cancers by en-
hanced CT imaging from the chest to the pelvis.
Clinicopathological data, such as age at the diagnosis of
bone metastasis, gender, the Eastern Cooperative Oncol-
ogy Group (ECOG) performance status scale, symptoms
at the diagnosis of bone metastasis, tumor localization,
differentiation, clinical or pathological stage (according to
the 14th edition of the Japanese classification of gastric
carcinoma to determine pathological stage [8]) at initial
diagnosis, treatment for primary tumor (surgery or
chemotherapy), treatment for bone metastasis (chemo-
therapy, radiotherapy, or best supportive care), and the
spread of bone metastasis, were determined from patient
records. The numerical values of serum alkaline phosphat-
ase (ALP), serum lactate dehydrogenase (LDH), carci-
noembryonic antigen (CEA), carbohydrate antigen (CA)
19-9, and CA125 were obtained from tests performed at
the time of the diagnosis of bone metastasis. When the
bone metastasis was observed at the same time as the
diagnosis of gastric cancer, we defined it as a synchronous
pattern of bone metastasis, while a metachronous pattern
of bone metastasis was defined as bone metastasis de-
tected at any time after the diagnosis of gastric cancer. For
some patients, only a computed tomography (CT) scan
was used in the diagnosis because bone metastasis was
evident, while many patients were diagnosed using a com-
bination of bone scintigraphy, positron emission tomog-
raphy (PET)-CT, and magnetic resonance imaging (MRI).
We estimated the overall survival after the diagnosis of
bone metastasis using the Kaplan-Meier product-limit
method. We also evaluated which clinicopathological
factors were associated with prognostic factors for sur-
vival using univariate and multivariate Cox proportional
hazards regression models. Statistical significance was
set at p < 0.05. All statistical analyses were performed
using SPSS Statistics software, version 19 (IBM Corp.,
Armonk, NY, USA).
Results
The median age of the 34 patients at the time the bone
metastasis was diagnosed was 66 years (Table 1). There
were 26 male patients and 8 females, and 19 patients
(55.9%) had undifferentiated adenocarcinoma. The treat-
ment for the primary tumor was surgery in 16 patients
(47.1%), and 10 of them had radical resection. Out of 18
patients (52.9%) who used chemotherapy for initial treat-
ment, 2 patients had surgery after chemotherapy with S1
Table 1 Patient demographics and pathologic features
Factors Patient
(n = 34)
Age (years) Median (range) 66 (39–78)
Gender Male 26 (76.5%)
Female 8 (23.5%)
ECOG performance status 0–1 16 (47.1%)
2–4 18 (52.9%)
Bone pain Present 11 (32.4%)
Absent 23 (67.6%)
Location Upper 1/3 5 (14.7%)
Middle 1/3 17 (50.0%)
Lower 1/3 5 (14.7%)
Whole stomach 7 (20.6%)
Histologic type Differentiated 15 (44.1%)
Undifferentiated 19 (55.9%)




Treatment for primary tumor Surgery 16 (47.1%)
Chemotherapy 18 (52.9%)
ALP (IU/L) Median (range) 375.5 (157–2743)
LDH (IU/L) Median (range) 249 (117–1481)
CEA Median (range) 8.6 (1.0–3508)
CA19-9 Median (range) 53.7 (0.6–1814.0)
CA125 Median (range) 20.3 (7.9–1099)
Diagnostic modality CT 30 (88.2%)
Bone scan 10 (29.4%)
MRI 9 (26.5%)
PET-CT 1 (2.9%)
Pattern of bone metastasis Synchronous 10 (29.4%)
Metachronous 24 (70.6%)
Number of bone metastases Single 12 (35.3%)
Multiple 22 (64.7%)
Extraosseous metastasis Present 26 (76.5%)
Absent 8 (23.5%)
Treatment of bone metastasis Chemotherapy 26 (76.5%)
Radiotherapy 5 (14.7%)
Best supportive care 4 (11.8%)
Abbreviations: ALP serum alkaline phosphatase, LDH lactate dehydrogenase, CEA
serum carcinoembryonic antigen, CA carbohydrate antigen, CT computed
tomography, MRI magnetic resonance imaging, PET positron emission tomography
aStage was according to the 14th edition of the Japanese classification of
gastric carcinoma
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and cisplatin. Eleven patients (32.4%) had bone pain at
the time the bone metastasis was diagnosed. The median
serum ALP and LDH levels at the time of bone metasta-
sis were 375.5 and 249 IU/L, respectively. To diagnose
the bone metastasis, CT scan was used for 30 patients
(29.4%), and 15 patients of them underwent bone scin-
tigraphy (9 patients), MRI (7 patients), and PET-CT (1
patient) after CT scan (Two patients underwent both
bone scintigraphy and and MRI).
Ten patients (29.4%) were diagnosed with bone metas-
tasis and gastric cancer at the same time, and 26 patients
(76.5%) had at least one other organ affected besides
their bones. Of the 24 patients who had metachronous
metastasis, the median interval from the diagnosis of
gastric cancer to the detection of bone metastasis was
398 days (range, 43–1799, data not shown).
The treatment of the bone metastasis consisted of
chemotherapy in 26 patients (76%), radiotherapy in 5 pa-
tients (15%), and 4 patients only received the best support-
ive care (12%). The most common sites of bone metastases
were the thoracic vertebrae (55.9%), pelvic bones (41.2%),
lumbar vertebrae (38.2%), and ribs (29.4%) (Table 2). Many
patients were treated with chemotherapy, such as S1-based
regimens, as first-line chemotherapy, and taxane-based or
irinotecan-based regimens as second and subsequent
chemotherapies, according to the recommendation of the
Japanese Gastric Cancer Treatment Guidelines for patients
who have progressive or recurrent gastric cancer [9]. Some
patients were treated with radiotherapy for a localized
tumor or local symptom relief.
The 6-month survival rate and the median survival
time after the diagnosis of bone metastasis were 63.8%
and 227.5 days, respectively (Fig. 1). A multivariate ana-
lysis revealed that metachronous metastasis (odds ratio
3.6; 95% confidence interval 1.1–11.7; p = 0.035) and
extraosseous metastasis (odds ratio 4.1; 95% confidence
interval 1.2–14.9; p = 0.028) were significant risk factors
for poor survival (Table 3).
Discussion
In this study, the 6-month survival rate and the median
survival time after the diagnosis of bone metastasis were
63.8% and 227.5 days, respectively. In univariate analysis,
only pattern of bone metastases (synchronous vs meta-
chronous) became an independent prognostic factor.
The multivariate analysis was carried out using the pat-
tern of bone metastases and variables pointed out to
affect prognosis in past reports [2, 7]. As a result, meta-
chronous metastasis and extraosseous metastasis were
significant risk factors for poor survival.
In the period of this study, there were 622 patients who
have been treated for gastric cancer for the first time in
our hospital, and 34 of them have been diagnosed with
bone metastasis. Most patients develop bone metastasis
within 2 years of gastric surgery [3]. In this study, the me-
dian interval from the diagnosis of gastric cancer to the
detection of bone metastasis was 398 days in the patients
who had metachronous metastasis, and the median inter-
val from the surgery to the detection of bone metastasis
was 562 days. Bone metastases from gastric cancer were
not unusual in a multicenter trial [10], and Turkoz et al.
suggested that bone metastases should be considered dur-
ing the follow-up of gastric cancer patients, even in the
early period [3]. Patients may have relatively long-term
survival if there is no extraosseous metastasis or local con-
trol for metastasis is possible, but it is difficult to diagnose
bone metastasis because the majority of affected patients
are asymptomatic and evaluations for bone metastases are
Table 2 Site of bone metastasis
Site of bone metastasis Patient
(n = 34)
Thoracic vertebrae 19 (55.9%)
Pelvic bones 14 (41.2%)
Lumbar vertebrae 13 (38.2%)
Ribs 10 (29.4%)
Cervical vertebrae 6 (17.6%)
Calvarium 4 (11.2%)
Scapula 3 (8.8%)
Lower extremity 3 (8.8%)
Upper extremity 2 (5.9%)
Clavicle 1 (2.9%)
Sternum 1 (2.9%)
Fig. 1 Overall survival of patients after the diagnosis of bone metastasis
Mikami et al. World Journal of Surgical Oncology  (2017) 15:8 Page 3 of 5
not indicated in routine practice [7]. In our study, there
were many cases that were discovered by chance during a
routine CT examination. Only 32.4% of patients com-
plained about symptoms, such as bone pain. In addition,
serum ALP, LDH, or tumor markers were not always high,
although there have been several reports that show such
serum parameters were useful for diagnosing bone metas-
tasis [11–13]. Ahn et al. suggested that an appropriate
modality, such as bone scintigraphy, is required to assess
bone metastasis at the time of the initial diagnosis and
during follow-up observations [5].
Since there were no prospective studies of therapeutic
regimens in gastric cancer patients with bone metastasis,
the optimal chemotherapy regimens were unknown [2]. In
this study, the treatment of metachronous bone metastasis
differed depending on the judgment of the attending phys-
ician, and there had been various treatments before bone
metastasis was recognized, while median survival time
(MST) of patients who were treated metachronous bone
metastasis with S1-based regimens or irinotecan-based reg-
imens was significantly longer than MST of other patients
(314 vs 87 days, p = 0.010). The Japanese Gastric Cancer
Treatment Guidelines recommend S1-based chemotherapy
for progressive or recurrent gastric cancer [9]. On the
other hand, since bone metastasis can cause disseminated
intravascular coagulation (DIC), the poor general condition
of the patient or the presence of thrombocytopenia and
severe anemia may make the patient ineligible for chemo-
therapy [14]. Hironaka et al. reported that sequential
methotrexate and 5-fluorouracil chemotherapy resulted in
a high rate of alleviation of DIC caused by bone metastasis
from gastric cancer [15]. In addition, the pain management
for patients with bone pain is important and radiation ther-
apy may be quite effective [5]. In recent years, it has been
reported that the incidence of epidermal growth factor
receptor (EGFR) mutations in the bone metastases was
high in the lung adenocarcinoma [16, 17]. Thus, EGFR
tyrosine kinase inhibitor therapies could be effective for
the type of adenocarcinoma. However, there are no reports
about genetic mutations in the bone metastases due to
gastric cancer. Identifying such mechanisms like gene mu-
tations may lead to the development of future treatment.
In our study, the diagnosis of bone metastasis was left to
the discretion of the attending physician and various
modalities were used, so we could not evaluate which diag-
nostic methods were appropriate. In addition, the treat-
ments varied depending on when the bone metastasis was
detected. Therefore, further investigations are necessary.
Conclusions
The prognosis of gastric cancer with bone metastasis was
poor, and metachronous metastasis and extraosseous me-
tastasis were shown to be poor prognostic factors. In
addition, ALP, LDH, and tumor markers are not always
high, so aggressive diagnosis using appropriate modalities
such as bone scan, MRI, or PET-CT may be necessary in
routine practice even in asymptomatic patients.
Table 3 Univariate and multivariate analyses of prognostic factors for survival
Univariate analysis Multivariate analysis
RR (95% CI) p value RR (95% CI) p value
Age ≥75
<75 1.8 (0.25–13.7) 0.54
Gender Male
Female 1.1 (0.45–2.9) 0.78
ECOG performance status 0–1
2–4 1.4 (0.57–3.4) 0.48 1.1 (0.41–2.8) 0.88
Bone pain Absent
Present 2.0 (0.90–4.5) 0.091 2.7 (0.93–8.1) 0.068
Histologic type Undifferentiated
Differentiated 1.1 (0.53–2.5) 0.73
Stagea I–III
IV 1.0 (0.46–2.2) 0.99
Pattern of bone metastasis Synchronous
Metachronous 2.8 (1.1–7.5) 0.038 3.6 (1.1–11.7) 0.035
Extraosseous metastasis Absent
Present 1.1 (0.47–2.8) 0.77 4.1 (1.2–14.9) 0.028
Abbreviations: CI confidential interval, ECOG Eastern Cooperative Oncology
aStage was according to the 14th edition of the Japanese classification of gastric carcinoma
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Abbreviations
ALP: Alkaline phosphatase; CA: Carbohydrate antigen; CEA: Carcinoembryonic
antigen; CT: Computed tomography; DIC: Disseminated intravascular
coagulation; ECOG: Eastern Cooperative Oncology Group; LDH: Lactate
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